GW completes Epidiolex submission
admin 31st October 2017 Uncategorised 0GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy. More: GW completes Epidiolex submission Source: News
read more